Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of FLUAD (MF59C.1-adjuvanted) Influenza Vaccine in Elderly Subjects (2007-2008 Formulation)
2007-000966-19Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2007
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Fluzone Trivalent in influenza, sponsored by Novartis. Primary endpoints: Immunogenicity by SRH at 21 days and Safety of single IM injection of FLUAD. Started Jun 2007; status: completed.
02
Drugs
Fluzone Trivalent
03
Conditions
influenza
Beyond the preview
Go deeper on 2007-000966-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000966-19.